The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
Constantine Tam, MBBS, MD, FRACP, FRCPA from the University of Melbourne, Melbourne, Australia discusses the safety and activity of the BTK inhibitor zanubrutinib (BGB-3111) plus obinutuzumab in follicular lymphoma and chronic lymphocytic leukemia (CLL) patients (NCT02569476). Prof. Tam explains that zanubrutinib is more specific than ibrutinib. When ibrutinib is combined with an antibody, results are often not as good as expected while zanubrutinib has little off-target selectivity. The Phase Ib study evaluates the combination of zanubrutinib and obinutuzumab and has shown that this combination is well-tolerated. Preliminary results are promising with response rates of approximately 70% and a high complete remission rate (CRR) in follicular lymphoma patients suggesting that this may be one of the most active combinations available for relapsed follicular lymphoma.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
